Company Description
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Feb 3, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 790 |
| CEO | Frank Lee |
Contact Details
Address: 5401 West Kennedy Boulevard, Suite 890 Tampa, Florida 33609 United States | |
| Phone | 813 553 6680 |
| Website | pacira.com |
Stock Details
| Ticker Symbol | PCRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001396814 |
| CUSIP Number | 695127100 |
| ISIN Number | US6951271005 |
| Employer ID | 51-0619477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Frank D. Lee | Chief Executive Officer and Director |
| Kristen Williams Esq., J.D. | Chief Administrative Officer and Secretary |
| David M. Stack | Advisor |
| Charles A. Reinhart III, CPA, M.B.A. | Executive Officer |
| Dr. Jonathan Slonin M.D. | Chief Medical Officer |
| Shawn M. Cross | Chief Financial Officer |
| Lauren Bullaro Riker | Principal Accounting Officer and Senior Vice President of Finance |
| Susan Mesco | Head of Investor Relations |
| Anthony Molloy III, Esq. | Chief Legal and Compliance Officer |
| Christopher C. Young | Chief Manufacturing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 8-K | Current Report |
| Mar 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 14, 2025 | DFAN14A | Filing |
| Mar 6, 2025 | 144 | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 15, 2025 | SCHEDULE 13G | Filing |